Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

@article{Mascelli1998PharmacodynamicPO,
  title={Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.},
  author={Mary Ann Mascelli and Ellen T. Lance and Lakshmi V. Damaraju and Carrie Lynne Wagner and Harlan F. Weisman and Robert Earl Jordan},
  journal={Circulation},
  year={1998},
  volume={97 17},
  pages={
          1680-8
        }
}
BACKGROUND The glycoprotein (GP) IIb/IIIa receptor antagonist abciximab is approved for use in high-risk percutaneous coronary interventions. The purpose of the present study was to establish the pharmacodynamic profile and platelet-bound life span of abciximab. METHODS AND RESULTS The pharmacodynamics of abciximab (inhibition of ex vivo platelet aggregation and GP IIb/IIIa receptor blockade) were measured in 41 individuals who were randomized to receive a 0.25-mg/kg bolus and a 12-hour… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 69 CITATIONS

Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease

  • Contemporary Cardiology
  • 2003
VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

A critical appraisal of platelet glycoprotein IIb/IIIa inhibition.

  • Journal of the American College of Cardiology
  • 2000
VIEW 14 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Antiplatelet Therapy in Interventional Cardiology: II. Glycoprotein IIb/IIIa Inhibitors

  • Journal of Thrombosis and Thrombolysis
  • 2000
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention.

  • Expert review of cardiovascular therapy
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

1998
2017

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 1 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 34 REFERENCES

Abciximab (ReoPro, chimeric 7E3 Fab) cross-reactivity withavb3 integrin receptors: a potential mechanism for the prevention of restenosis

MT Nakada, RE Jordan, DM. Knight
  • J Am Coll Cardiol. 1997;29:243A. Abstract. Mascelli et al May
  • 1998
VIEW 1 EXCERPT

Preclinical development of c7E3 Fab: a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GP IIb/IIIa

RE Jordan, CA Wagner, +5 authors BS. Coller
  • 1996

Reversal of the anti-platelet effects of chimeric 7E3 Fab treatment by platelet transfusion in cynomolgus monkeys

CL Wagner, MR Cunningham, +3 authors RE. Jordan
  • Thromb Haemost. 1995;73:1313
  • 1995

Similar Papers

Loading similar papers…